rian.ie - Results

A A A

Current Search:	'Cancer' in all fields;

Displaying Results 151 - 175 of 3687 on page 7 of 148

Mark

Low 25-hydroxyvitamin D levels in peopel with a solid tumor cancer diagnosis: the tip of the iceberg? (2014)

WALSH, THOMAS

Mark

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. (2014)

MARTIN, CARA; SHEILS, ORLA; SMYTH, PAUL; FINN, STEPHEN; O'LEARY, JOHN; GALLAGHER, ...

Mark

MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer (2009)

Lowery, Aoife J.; Miller, Nicola; Devaney, Amanda; McNeill, Roisin E.; Davoren, Roisin ...

Mark

Bile acids destabilise HIF-1α and promote anti-tumour phenotypes in cancer cell models (2016)

Phelan, John P.; Reen, F. Jerry; Dunphy, Niall; O'Connor, Rosemary; O'Gara, F...

Mark

Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer (2015)

SHEILS, ORLA; O'LEARY, JOHN; GALLAGHER, MICHAEL; SPILLANE, CATHY

Mark

‘Moving on’ from cancer: the effects of engaging in a 12 week community-based exercise programme on cancer survivors’ physical and psychological well-being (2016)

Cooney, Mairead; Woods, Catherine; Moyna, Niall; O'Leary, Emer; Furlong, Bróna; Wa...

Mark

A theoretical framework to guide a study exploring cancer related fatigue (2017)

O'Regan, Patricia; Landers, Margaret; Hegarty, Josephine

Mark

Bioconjugated gold nanoparticles enhance cellular uptake: a proof of concept study for siRNA delivery in prostate cancer cells (2016)

Guo, Jianfeng; O'Driscoll, Caitríona M.; Holmes, Justin D.; Rahme, Kamil

Mark

Factors driving inequality in prostate cancer survival: a population based study (2014)

Burns, Richéal M.; Sharp, Linda; Sullivan, Francis J.; Deady, Sandra E.; Drummond, Fran...

Mark

Molecular Mechanisms of Advanced Prostate Cancer (2018)

BRADY, LAUREN MARIE

Mark

Multidisciplinary Rehabilitation in Oesophago-gastric Cancer Surviorship (2018)

O'NEILL, LINDA MARIE

Mark

Metabolic Targeting of Breast Cancer Cells With the 2-Deoxy-D-Glucose and the Mitochondrial Bioenergetics Inhibitor MDIVI-1. (2018)

Lucantoni, Federico; Düssmann, Heiko; Prehn, Jochen HM

Mark

Standards for the management of cancer-related pain across Europe. A position paper from the EFIC Task Force on Cancer Pain (2018)

Bennett, Michael I.; Eisenberg, Elon; Ahmedzai, Sam H.; Bhaskar, Arun; O'Brien, To...

Mark

Evaluate the effectiveness and sustainability of OptiMal as a self-management intervention for cancer survivors (2019)

BOLAND, LAUREN

Mark

IL-1 family members in cancer; two sides to every story (2019)

Baker, Kevin J.; Houston, Aileen M.; Brint, Elizabeth K.

Mark

Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones (2019)

Potter, Shirley M.; Dwyer, Róisín M.; Curran, Catherine E.; Hennessy, Emer; Harrington,...

Mark

Mode of prostate cancer detection is associated with the psychological wellbeing of survivors: results from the PiCTure study (2015)

Drummond, Frances J.; O'Leary, Eamonn; Gavin, Anna T.; Kinnear, Heather; Linda, Sharp

Mark

The microbiota of breast tissue and its association with breast cancer (2016)

Urbaniak, Camilla; Gloor, Gregory B.; Brackstone, Muriel; Scott, Leslie; Tangney, Mark;...

Mark

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. (2018)

O'Driscoll, Lorraine; Eustace, Alex J.; Conlon, Neil T.; McDermott, Martina S.J.; ...

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. (2018)

O'Driscoll, Lorraine; Eustace, Alex J.; Conlon, Neil T.; McDermott, Martina S.J.; Browne, Brigid C.; O'Leary, Patrick; Holmes, Frankie A.; Espina, Virginia; Liotta, Lance A.; O'Shaughnessy, Joyce; Gallagher, Clair; Rani, Sweta; Madden, Stephen F.; O'Brien, Neil A.; Ginther, Charles; Slamon, Dennis; Walsh, Naomi; Gallagher, William M.; Zagozdzon, Radoslaw; Watson, William R.

Abstract:

Background: Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug. Induction of apoptotic cell death is a key mechanism of action of lapatinib in HER2-positive breast cancer cells. Methods: We examined alterations in regulation of the intrinsic and extrinsic apoptosis pathways in cell line models of acquired lapatinib resistance both in vitro and in patient samples from the NCT01485926 clinical trial, and investigated potential strategies to exploit alterations in apoptosis signalling to overcome lapatinib resistance in HER2-positive breast cancer. Results: In this study, we examined two cell lines models of acquired lapatinib resistance (SKBR3-L and HCC1954-L) and showed that lapatinib does not induce apoptosis in these cells. We identified alterations in members of the BCL-2 family of proteins, in particular MCL-1 and BA...